{
  "info": {
    "company_name": "Moderna Inc.",
    "company_url": "https://www.responsibilityreports.com/Company/moderna-inc",
    "ticker_name": "MRNA",
    "exchange": "NASDAQ",
    "industry": "Biotechnology",
    "sector": "Healthcare",
    "about_company": "Moderna scientists designed the company\u2019s prophylactic vaccines modality to prevent infectious diseases. More than 1,900 participants, prior to enrolling the Phase 3 study of mRNA-1273, have been enrolled in Moderna\u2019s infectious disease vaccine clinical studies under health authorities in the U.S., Europe and Australia. Clinical data demonstrate that Moderna\u2019s proprietary vaccine technology\u2026More",
    "num_employees": "501-1000 Employees",
    "location": "Based in Cambridge, Massachusetts"
  },
  "reports": [
    {
      "pdf_url": "https://www.responsibilityreports.com/HostedData/ResponsibilityReports/PDF/NASDAQ_MRNA_2021.pdf",
      "report_name": "NASDAQ_MRNA_2021"
    }
  ]
}